$SKIN
Beauty Health Co Stock $skin

$skin Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024022336 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$90.59M	$81.40M
YoY Change	-22.88%	-5.65%
Cost Of Revenue	$49.65M	$33.04M
YoY Change	0.1%	2.7%
Gross Profit	$40.94M	$48.36M
YoY Change	-39.68%	-10.61%
Gross Profit Margin	45.19%	59.41%
Selling, General & Admin	$61.89M	$62.55M
YoY Change	-20.79%	-9.46%
% of Gross Profit	151.18%	129.33%
Research & Development	$1.159M	$2.807M
YoY Change	-59.77%	20.16%
% of Gross Profit	2.83%	5.8%
Depreciation & Amortization	$7.928M	$2.773M
YoY Change	-19.93%	51.2%
% of Gross Profit	19.36%	5.73%
Operating Expenses	$63.05M	$65.35M
YoY Change	-22.18%	-8.49%
Operating Profit	-$22.11M	-$16.99M
YoY Change	68.2%	-1.84%
Interest Expense	$598.0K	$3.029M
YoY Change	-77.73%	-11.35%
% of Operating Profit
Other Income/Expense, Net	$17.32M	$16.09M
YoY Change	48.89%	3748.56%
Pretax Income	-$151.0K	-$1.338M
YoY Change	-112.89%	-94.84%
Income Tax	-$353.0K	-$700.0K
% Of Pretax Income
Net Earnings	$202.0K	-$679.0K
YoY Change	-94.0%	-96.95%
Net Earnings / Revenue	0.22%	-0.83%
Basic Earnings Per Share	$0.00	-$0.01
Diluted Earnings Per Share	-$0.10	-$0.10
COMMON SHARES
Basic Shares Outstanding	123.6M shares	123.4M shares
Diluted Shares Outstanding	141.9M shares	144.5M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$349.5M	$444.6M
YoY Change	-36.42%	-16.47%
Cash & Equivalents	$349.5M	$444.6M
Short-Term Investments
Other Short-Term Assets	$21.13M	$25.60M
YoY Change	-31.71%	17.97%
Inventory	$77.14M	$95.72M
Prepaid Expenses
Receivables	$41.41M	$47.67M
Other Receivables	$401.0K	$1.204M
Total Short-Term Assets	$489.6M	$614.8M
YoY Change	-36.24%	-17.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.66M	$28.43M
YoY Change	-22.33%	-16.38%
Goodwill	$124.8M	$125.4M
YoY Change	-0.42%	0.15%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$15.53M	$15.78M
YoY Change	-7.92%	0.99%
Total Long-Term Assets	$222.2M	$229.9M
YoY Change	-7.23%	-6.7%
TOTAL ASSETS
Total Short-Term Assets	$489.6M	$614.8M
Total Long-Term Assets	$222.2M	$229.9M
Total Assets	$711.8M	$844.7M
YoY Change	-29.34%	-15.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.69M	$37.31M
YoY Change	-9.17%	8.69%
Accrued Expenses	$24.04M	$24.40M
YoY Change	-52.1%	85.53%
Deferred Revenue	$3.875M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$75.43M	$93.57M
YoY Change	-8.89%	29.36%
LONG-TERM LIABILITIES
Long-Term Debt	$550.6M	$665.5M
YoY Change	-25.21%	-9.48%
Other Long-Term Liabilities	$1.849M	$2.617M
YoY Change	-92.47%	-92.91%
Total Long-Term Liabilities	$1.849M	$2.617M
YoY Change	-99.76%	-99.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$75.43M	$93.57M
Total Long-Term Liabilities	$1.849M	$2.617M
Total Liabilities	$642.6M	$781.4M
YoY Change	-24.0%	-7.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$479.3M	-$479.5M
YoY Change	21.15%	18.77%
Common Stock	$12.00K	$12.00K
YoY Change	-14.29%	-14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$69.19M	$63.30M
YoY Change
Total Liabilities & Shareholders Equity	$711.8M	$844.7M
YoY Change	-29.34%	-15.1%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	$202.0K	-$679.0K
YoY Change	-94.0%	-96.95%
Depreciation, Depletion And Amortization	$7.928M	$2.773M
YoY Change	-19.93%	51.2%
Cash From Operating Activities	$6.201M	-$16.85M
YoY Change	-71.77%	29.55%
INVESTING ACTIVITIES
Capital Expenditures	$2.038M	$344.0K
YoY Change	-36.69%	-85.17%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$2.038M	-$1.802M
YoY Change	-36.69%	-91.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-98.75M	-$58.62M
YoY Change	6287.39%	2570.52%
NET CHANGE
Cash From Operating Activities	6.201M	-$16.85M
Cash From Investing Activities	-2.038M	-$1.802M
Cash From Financing Activities	-98.75M	-$58.62M
Net Change In Cash	-94.59M	-$77.27M
YoY Change	-649.89%	109.48%
FREE CASH FLOW
Cash From Operating Activities	$6.201M	-$16.85M
Capital Expenditures	$2.038M	$344.0K
Free Cash Flow	$4.163M	-$17.20M
YoY Change	-77.79%	12.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4598000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	33042000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	32174000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-679000	usd
CY2024Q1	skin	Syndeo Program Reserves SyndeoProgramReserves	8314000	usd
CY2023Q4	skin	Syndeo Program Reserves SyndeoProgramReserves	21009000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4648000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3443000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2759000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	48361000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	54104000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	33684000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	38699000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2807000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2336000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28861000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30379000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	65352000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	71414000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16991000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17310000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	3029000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3417000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	5356000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	4315000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16087000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	418000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1464000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	9076000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1297000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1149000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1338000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23921000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-659000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3662000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-679000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20259000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1047000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	888000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1726000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19371000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123120426	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132420762	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144477208	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132420762	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	167053000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20259000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2195000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2034000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3577000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1310000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	152408000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	59390000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-679000	usd
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1005000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6636000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1047000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	63295000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20259000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6636000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3577000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4985000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3874000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	2773000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	1834000	usd
CY2024Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	890000	usd
CY2023Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	548000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	951000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1058000	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	5479000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	3337000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	656000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1093000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1464000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	9076000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	16087000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1030000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-279000	usd
CY2024Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3108000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-515000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5879000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4793000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11081000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13905000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1936000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1325000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-20786000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3829000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	1948000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	2088000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16854000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13010000	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1458000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2450000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	344000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2319000	usd
CY2024Q1	skin	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	usd
CY2023Q1	skin	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	16915000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1802000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21684000	usd
CY2024Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	57750000	usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	868000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2195000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-58618000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2195000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-77274000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-36889000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1117000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	974000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	523025000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568197000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	444634000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	532282000	usd
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	81403000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86278000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	81403000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	86278000	usd
CY2024Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	23793000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	24406000	usd
CY2024Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	71928000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	66915000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	95721000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	91321000	usd
CY2024Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7296000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10458000	usd
CY2024Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	5572000	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	7565000	usd
CY2024Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2588000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4005000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15456000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22028000	usd
CY2024Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4328000	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4971000	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	4219000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2344000	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3783000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3914000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12065000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8617000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24395000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19846000	usd
CY2024Q1	us-gaap	Nontrade Receivables NontradeReceivables	12000000	usd
CY2023Q4	us-gaap	Nontrade Receivables NontradeReceivables	15000000	usd
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	7000000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	6000000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	5000000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	2000000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	4000000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	2000000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	2000000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	22357000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	19953000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	12048000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	14226000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	125818000	usd
CY2024Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-453000	usd
CY2024Q1	us-gaap	Goodwill Goodwill	125365000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	150530000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	92125000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	58405000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	149392000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	87269000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	62123000	usd
CY2024Q1	us-gaap	Debt Instrument Repurchased Face Amount DebtInstrumentRepurchasedFaceAmount	75000000	usd
CY2024Q1	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	0.77
CY2024Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	57800000	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	16100000	usd
CY2024Q1	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	1200000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-700000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3700000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.493
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.153
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	300000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1100000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6636000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3577000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	36700000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2023Q3	skin	Litigation Settlement Amount Awarded From Other Party Quarterly Payment Amount LitigationSettlementAmountAwardedFromOtherPartyQuarterlyPaymentAmount	100000	usd
CY2023Q3	skin	Number Of Quarterly Payments NumberOfQuarterlyPayments	13	payment
CY2023Q3	skin	Litigation Settlement Amount Awarded From Other Party Quarterly Payment Amount LitigationSettlementAmountAwardedFromOtherPartyQuarterlyPaymentAmount	100000	usd
CY2023Q3	us-gaap	Litigation Settlement Amount Awarded From Other Party LitigationSettlementAmountAwardedFromOtherParty	1400000	usd
CY2023Q4	us-gaap	Proceeds From Legal Settlements ProceedsFromLegalSettlements	100000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	320000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	skin	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123453419	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123453419	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	122899002	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	122899002	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-679000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20259000	usd
CY2024Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-13072000	usd
CY2023Q1	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13751000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-20259000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123120426	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132420762	shares
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	21356782	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144477208	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132420762	shares
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2023Q4	skin	Syndeo Program Reserves SyndeoProgramReserves	21009000	usd
CY2024Q1	skin	Syndeo Program Usage SyndeoProgramUsage	12695000	usd
CY2024Q1	skin	Syndeo Program Reserves SyndeoProgramReserves	8314000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	167100000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	152400000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1149000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23921000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20259000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19371000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-20259000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-515000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13905000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1325000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3829000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-022336-index-headers.html	Edgar Link	pending
0001628280-24-022336-index.html	Edgar Link	pending
0001628280-24-022336.txt	Edgar Link	pending
0001628280-24-022336-xbrl.zip	Edgar Link	pending
ex311-2024q110q.htm	Edgar Link	pending
ex312-2024q110q.htm	Edgar Link	pending
ex321-2024q110q.htm	Edgar Link	pending
ex322-2024q110q.htm	Edgar Link	pending
exhibit103edgarversion-s.htm	Edgar Link	pending
exhibit103edgarversion-s001.jpg	Edgar Link	pending
exhibit103edgarversion-s002.jpg	Edgar Link	pending
exhibit103edgarversion-s003.jpg	Edgar Link	pending
exhibit103edgarversion-s004.jpg	Edgar Link	pending
exhibit103edgarversion-s005.jpg	Edgar Link	pending
exhibit103edgarversion-s006.jpg	Edgar Link	pending
exhibit103edgarversion-s007.jpg	Edgar Link	pending
exhibit104edgarversion-s.htm	Edgar Link	pending
exhibit104edgarversion-s001.jpg	Edgar Link	pending
exhibit104edgarversion-s002.jpg	Edgar Link	pending
exhibit104edgarversion-s003.jpg	Edgar Link	pending
exhibit104edgarversion-s004.jpg	Edgar Link	pending
exhibit104edgarversion-s005.jpg	Edgar Link	pending
exhibit104edgarversion-s006.jpg	Edgar Link	pending
exhibit104edgarversion-s007.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
skin-20240331.htm	Edgar Link	pending
skin-20240331.xsd	Edgar Link	pending
skin-20240331_def.xml	Edgar Link	unprocessable
skin-20240331_lab.xml	Edgar Link	unprocessable
skin-20240331_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
skin-20240331_cal.xml	Edgar Link	unprocessable
skin-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SKIN
Beauty Health Co Stock $skin

2024 Q2 Form 10-Q Financial Statement

#000162828024022336 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKIN Beauty Health Co Stock $skin

2024 Q2 Form 10-Q Financial Statement

#000162828024022336 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SKIN
Beauty Health Co Stock $skin